Gastrointestinal Perforation After Rituximab Therapy in Mantle Cell Lymphoma: A Case Report

In this case study, a 55-year-old male patient with mantle cell lymphoma (MCL) develops a gastrointestinal perforation shortly after beginning rituximab treatment. The authors stress that although the Mantle Cell Lymphoma International Prognostic Index (MIPI) is helpful in determining time to treatment failure and overall survival, more research is needed on determining patients’ potential for developing MCL treatment complications.

Case Reports in Oncology